AXSM250117C50000
- 36.89
- 0.000.00%
Axsome Therapeutics Newsroom
RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Cuts Target Price to $139
Axsome Therapeutics (AXSM) Gets a Buy From RBC Capital
Axsome Therapeutics Analyst Ratings
Piper Sandler Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $117
Piper Sandler Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $180
Optimistic Buy Rating for Axsome Therapeutics Driven by Auvelity's Strong Market Performance and Potential
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $125
TD Cowen Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $125
Needham Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $133
Needham Reiterates Buy on Axsome Therapeutics, Maintains $133 Price Target
Axsome Therapeutics Analyst Ratings
Truist Financial Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $180
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $125
Truist Financial Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $180
RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $140
RBC Lifts Price Target on Axsome Therapeutics to $140 From $138, Keeps Outperform Rating
Needham Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $133
Axsome Therapeutics Analyst Ratings
William Blair Maintains Axsome Therapeutics(AXSM.US) With Buy Rating